Odonate, Inc. (ODTC)
OTCMKTS · Delayed Price · Currency is USD
150,000
+10,000 (7.14%)
At close: Feb 4, 2025
Odonate Company Description
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer.
The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023.
The company was founded in 2013 and is based in New York, New York.
Odonate, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Shell Companies |
| Sector | Financials |
| Employees | 145 |
| CEO | Kevin Tang |
Contact Details
Address: 3 East 28th Street New York, Delaware 10016 United States | |
| Phone | 332 206 0935 |
| Website | odonate.com |
Stock Details
| Ticker Symbol | ODTC |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US6760791060 |
| SIC Code | 9995 |
Key Executives
| Name | Position |
|---|---|
| Kevin C. Tang | Chairman and Chief Executive Officer |
| Michael S. Hearne CPA | Chief Financial Officer and Principal Accounting Officer |
| Ryan Cole | Senior Vice President of Operations |
| Dr. Steven S. Pfeiffer Ph.D. | Senior Vice President of Technical Operations |